Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA deputy commissioner system needs revision, McKenna & Cuneo partner Pilot advises.

This article was originally published in The Gray Sheet

Executive Summary

FDA DEPUTY COMMISSIONER STRUCTURE NEEDS REVISION, McKENNA & CUNEO PARTNER Larry Pilot maintained at a Washington Legal Foundation conference March 25 in Washington, D.C. Pilot declared that the replacement for former Commissioner Kessler should "take a good look at the organization. Analyze what personnel are doing in relation to the organization [and] in relation to the expectation of Congress. In particular, I would advise the commissioner to do away with this multiple deputy commissioner system."
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel